Liposomal Bupivacaine Versus Ropivacaine for Preperitoneal Infiltration Analgesia in Upper Abdominal Laparotomy: A Randomized Double-Blind Controlled Trial

What this Trial Is About

Researchers are evaluating the pain relief and anti-inflammatory effects of two local anesthetic drugs, liposomal bupivacaine and ropivacaine, in patients undergoing upper abdominal open surgery. This trial focuses on managing postoperative pain, which is often moderate to severe and can delay recovery and reduce quality of life. The study aims to see how these drugs, administered before closing the abdomen, compare in controlling pain and inflammation after surgery. Participants are randomly assigned to receive either liposomal bupivacaine or ropivacaine injected into the preperitoneal space along the surgical incision before the abdomen is closed. Liposomal bupivacaine is a newer, long-acting formulation designed to release medication over 48 to 72 hours, while ropivacaine is a standard local anesthetic. Both groups follow the same anesthesia and postoperative pain management protocols apart from the local anesthetic injection. During the study, participants will be closely monitored with pain scores recorded on the first day after surgery and other measures tracked over the first three days, including opioid use, sleep quality, recovery scales, and inflammation markers like C-reactive protein. Researchers will also observe complications and hospital stay length. Follow-up will assess postoperative complications up to one month after surgery, providing a comprehensive evaluation of each drug's clinical value in pain control.

Liposomal Bupivacaine Versus Ropivacaine for Preperitoneal Infiltration Analgesia in Upper Abdominal Laparotomy